We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Retain PAHC Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Phibro Animal Health's Animal Health sales rose 13% in fiscal third-quarter 2026.
PAHC added 37 MFA product lines across about 80 countries through the Zoetis acquisition.
Phibro faces near-term risk from Brazil's antimicrobial transition, which could pressure profitability.
Phibro Animal Health Corporation (PAHC - Free Report) is well-positioned for growth in the coming quarters, as its Animal Health business continues to gain momentum, bolstered by the addition of Zoetis’ medicated feed additive (MFA) portfolio. Its established operations and broad sales, marketing and distribution network give the company room to expand internationally. A strong financial position adds to the stock’s appeal. However, macroeconomic challenges and near-term uncertainty surrounding Brazil’s antimicrobial transition could weigh on Phibro’s financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has risen 11.3% against the industry’s 25.2% fall and the S&P 500 composite’s 23.4% growth.
The renowned animal health and mineral nutrition company has a market capitalization of $1.40 billion. PAHC has an earnings yield of 9.6% compared with the industry’s yield of 2.6%. PAHC surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16.2%.
Let’s delve deeper.
Tailwinds Supporting PAHC Stock
Animal Health Business Growth Continues: Phibro’s animal health products, including MFAs, vaccines and nutritional specialty products, support animal nutrition and help manage disease outbreaks across major food animal species. The company’s leading MFA portfolio was further bolstered by the integration of Zoetis’ MFA business, which added more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China.
In the third quarter of fiscal 2026, Animal Health net sales increased 13% year over year, reflecting growth across MFAs, nutritional specialties and vaccines. The acquired MFA business generated a full quarter of revenues, up 25% versus last year, while legacy MFA sales increased 5% on demand in North America and certain antimicrobials sold by the ethanol performance business. Nutritional Specialty saw higher demand in North America and higher companion animal sales, while vaccine sales growth was driven by higher sales demand in Israel and higher sales of autogenous vaccines.
Image Source: Zacks Investment Research
Potential in Emerging Markets: The company’s global footprint extends to key high-growth regions, including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries, and South Africa and other countries in Africa. The current strategy remains focused on regions where livestock production is consolidated in large commercial farms, which supports product adoption and recurring demand. In third-quarter fiscal 2026, net sales in Europe, the Middle East and Africa increased 14% year over year, while Asia Pacific sales rose 9%. Latin America and Canada sales jumped 7%, reflecting continued demand across the region. This geographic balance helps offset uneven species cycles and supports management’s expectation for fiscal 2026 net sales growth.
Stable Solvency Structure: Phibro continues to prioritize returning capital through dividends while managing leverage. At the end of third-quarter fiscal 2026, cash and short-term investments were $77.5 million. Total debt was $740.9 million, implying a 3.1 gross leverage ratio and a 2.8 net leverage ratio. Subsequent to the quarter-end, Phibro increased revolving credit commitments by $125 million to $435 million, strengthening liquidity. During the third quarter, the company paid a quarterly dividend of $0.12 per share, or $4.9 million in aggregate.
What Ails Phibro?
Macroeconomic and Trade Policy Risks Remain: Phibro operates in markets exposed to sanctions, bans and broader military conflicts, including the ongoing Russia-Ukraine war. Changes in U.S. trade policy, tariffs and trade agreements could also disrupt its supply chain and raise the cost of key materials. The company has built inventory ahead of tariffs and to meet higher customer demand, which has reduced cash generation and increased working capital needs. Phibro is pursuing the potential recovery of certain U.S. tariffs already paid, but the timing and amount of any refund remain uncertain, and no benefit has been recorded.
Brazil’s Antimicrobial Transition Creates Near-Term Uncertainty: After the fiscal third-quarter end, Brazil implemented a new regulatory framework that removes growth promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin, with a 180-day transition period. Management is working with regulators and industry to ensure a smooth transition and maintain customer supply. However, the timing of therapeutic approvals and the shift to prescription-based demand remain uncertain. With $26 million in fiscal 2025 sales and above-average margins, virginiamycin disruptions in Brazil could weigh on profitability.
PAHC Stock Estimate Trend
The Zacks Consensus Estimate for Phibro’s fiscal 2026 earnings per share (EPS) projects 47.4% growth to $3.08. The estimate has remained constant in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.49 billion. This suggests a 14.8% rise from the year-ago reported number.
Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 42.3% against the industry’s 6.3% fall over the past year.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% compared to the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 5% against the industry’s 6.2% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Should You Continue to Retain PAHC Stock in Your Portfolio?
Key Takeaways
Phibro Animal Health Corporation (PAHC - Free Report) is well-positioned for growth in the coming quarters, as its Animal Health business continues to gain momentum, bolstered by the addition of Zoetis’ medicated feed additive (MFA) portfolio. Its established operations and broad sales, marketing and distribution network give the company room to expand internationally. A strong financial position adds to the stock’s appeal. However, macroeconomic challenges and near-term uncertainty surrounding Brazil’s antimicrobial transition could weigh on Phibro’s financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has risen 11.3% against the industry’s 25.2% fall and the S&P 500 composite’s 23.4% growth.
The renowned animal health and mineral nutrition company has a market capitalization of $1.40 billion. PAHC has an earnings yield of 9.6% compared with the industry’s yield of 2.6%. PAHC surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16.2%.
Let’s delve deeper.
Tailwinds Supporting PAHC Stock
Animal Health Business Growth Continues: Phibro’s animal health products, including MFAs, vaccines and nutritional specialty products, support animal nutrition and help manage disease outbreaks across major food animal species. The company’s leading MFA portfolio was further bolstered by the integration of Zoetis’ MFA business, which added more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China.
In the third quarter of fiscal 2026, Animal Health net sales increased 13% year over year, reflecting growth across MFAs, nutritional specialties and vaccines. The acquired MFA business generated a full quarter of revenues, up 25% versus last year, while legacy MFA sales increased 5% on demand in North America and certain antimicrobials sold by the ethanol performance business. Nutritional Specialty saw higher demand in North America and higher companion animal sales, while vaccine sales growth was driven by higher sales demand in Israel and higher sales of autogenous vaccines.
Image Source: Zacks Investment Research
Potential in Emerging Markets: The company’s global footprint extends to key high-growth regions, including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries, and South Africa and other countries in Africa. The current strategy remains focused on regions where livestock production is consolidated in large commercial farms, which supports product adoption and recurring demand. In third-quarter fiscal 2026, net sales in Europe, the Middle East and Africa increased 14% year over year, while Asia Pacific sales rose 9%. Latin America and Canada sales jumped 7%, reflecting continued demand across the region. This geographic balance helps offset uneven species cycles and supports management’s expectation for fiscal 2026 net sales growth.
Stable Solvency Structure: Phibro continues to prioritize returning capital through dividends while managing leverage. At the end of third-quarter fiscal 2026, cash and short-term investments were $77.5 million. Total debt was $740.9 million, implying a 3.1 gross leverage ratio and a 2.8 net leverage ratio. Subsequent to the quarter-end, Phibro increased revolving credit commitments by $125 million to $435 million, strengthening liquidity. During the third quarter, the company paid a quarterly dividend of $0.12 per share, or $4.9 million in aggregate.
What Ails Phibro?
Macroeconomic and Trade Policy Risks Remain: Phibro operates in markets exposed to sanctions, bans and broader military conflicts, including the ongoing Russia-Ukraine war. Changes in U.S. trade policy, tariffs and trade agreements could also disrupt its supply chain and raise the cost of key materials. The company has built inventory ahead of tariffs and to meet higher customer demand, which has reduced cash generation and increased working capital needs. Phibro is pursuing the potential recovery of certain U.S. tariffs already paid, but the timing and amount of any refund remain uncertain, and no benefit has been recorded.
Brazil’s Antimicrobial Transition Creates Near-Term Uncertainty: After the fiscal third-quarter end, Brazil implemented a new regulatory framework that removes growth promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin, with a 180-day transition period. Management is working with regulators and industry to ensure a smooth transition and maintain customer supply. However, the timing of therapeutic approvals and the shift to prescription-based demand remain uncertain. With $26 million in fiscal 2025 sales and above-average margins, virginiamycin disruptions in Brazil could weigh on profitability.
PAHC Stock Estimate Trend
The Zacks Consensus Estimate for Phibro’s fiscal 2026 earnings per share (EPS) projects 47.4% growth to $3.08. The estimate has remained constant in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.49 billion. This suggests a 14.8% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 42.3% against the industry’s 6.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% compared to the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 5% against the industry’s 6.2% decline over the past year.